Addex to participate in the h.c. wainwright 26th annual global investment conference

Geneva, switzerland, september 4, 2024 - addex therapeutics (six/nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that ceo, tim dyer, will be attending the h.c. wainwright 26th annual global investment conference taking place september 9 – 11, 2024, at the lotte new york palace hotel.
ADXN Ratings Summary
ADXN Quant Ranking